Beyond Pills: Your Guide to Drug-Free Neuromodulation for Migraine

Migraine treatment has expanded dramatically in recent years. While medications remain a cornerstone of care, many people living with migraine either cannot tolerate certain drugs, do not respond well to them, or prefer non-drug approaches whenever possible.

Neuromodulation represents one of the most promising non-pharmacological options. These therapies use targeted electrical or magnetic stimulation to influence the nervous system and alter the pathways involved in migraine. Unlike medications that work primarily through chemical mechanisms, neuromodulation devices act directly on neural circuits that regulate pain processing.

Headache specialist Dr. Stewart Tepper has been deeply involved in research on neuromodulation therapies and has helped evaluate several of the devices currently available. Understanding how these tools work—and when they may be appropriate—can help patients and clinicians make more informed treatment decisions.

What Neuromodulation Means in Migraine Care

Neuromodulation refers to the use of electrical, magnetic, or vibrational stimulation to influence nerve activity and brain pathways involved in migraine.

Most current migraine neuromodulation therapies are noninvasive, meaning they are used externally on the head, neck, or arm. Patients typically place the device on the body and activate it during a migraine attack or at scheduled intervals for prevention.

These devices are portable and designed for home use. In the United States, they are classified by the FDA as “nonsignificant risk” devices, meaning they generally carry very low rates of serious side effects.

Neuromodulation therapies differ from medications in an important way. While drugs typically target specific molecules—such as CGRP in modern migraine treatments—neuromodulation affects broader neural networks and pathways involved in migraine generation and pain processing.

This means the therapy may influence multiple mechanisms at once, including some that researchers may not yet fully understand.

Acute Treatment and Prevention in One Approach

One unique aspect of neuromodulation is that many devices can be used both acutely to stop a migraine attack and preventively to reduce attack frequency.

The distinction often depends on how frequently the device is used or which stimulation settings are selected.

For example:

• A device may deliver a longer or stronger stimulation session during an acute attack.

• The same device may use shorter daily sessions to reduce the likelihood of future attacks.

This dual functionality offers an advantage over some medications that are designed exclusively for either acute treatment or prevention.

Another key advantage is that neuromodulation does not cause medication overuse headache, a condition that can occur when certain acute medications are taken too frequently.

Advantages of Neuromodulation Therapies

Neuromodulation offers several potential benefits for people living with migraine.

These include:

• Very low risk of serious side effects

• No risk of medication overuse headache

• Ability to treat migraine without drugs

• Potential for both acute and preventive treatment

• Compatibility with existing medications

For people who have not responded well to medications, these devices may provide an additional layer of treatment.

For others, neuromodulation may serve as an alternative approach when medications are contraindicated, poorly tolerated, or simply undesirable.

Six Neuromodulation Devices Currently Available

Several neuromodulation devices have received FDA clearance for migraine treatment. Each device uses a different mechanism to stimulate specific nerves or brain pathways.

1. External Trigeminal Nerve Stimulation (Cefaly)

Cefaly is one of the earliest neuromodulation devices cleared for migraine treatment.

The device attaches to the forehead using a sticky electrode and stimulates branches of the trigeminal nerve, which plays a major role in migraine pain.

It has two main settings:

• Acute treatment: approximately one hour of stimulation during an attack

• Preventive treatment: about 20 minutes daily

The stimulation sends inhibitory signals to pain pathways in the brainstem and may also reduce activity in the brain’s “pain matrix” over time.

One challenge with Cefaly is that some users initially find the stimulation uncomfortable. Gradual increases in stimulation intensity over several weeks can improve tolerance.

2. HeadaTerm

HeadaTerm is another trigeminal nerve stimulator that functions similarly to Cefaly.

It is applied to the forehead and provides electrical stimulation to trigeminal nerve branches.

Unlike Cefaly, which automatically increases intensity over time, HeadaTerm allows users to manually adjust stimulation levels through several settings.

The device is generally less expensive than Cefaly but has fewer FDA-cleared indications.

3. Single-Pulse Transcranial Magnetic Stimulation (sTMS)

The sTMS device, known as SAVI Dual, uses magnetic pulses applied to the back of the head.

These pulses travel through the brain and may interrupt migraine processes in several ways.

One mechanism involves stopping cortical spreading depression, a wave of brain activity associated with migraine aura.

Another likely mechanism involves the thalamus, a central relay station that transmits pain signals to higher brain regions.

By inhibiting thalamic signaling, the magnetic pulse may reduce migraine pain.

This device has been cleared for both acute and preventive migraine treatment and can be used in adolescents as young as 12.

However, the device is relatively expensive and typically requires an ongoing rental arrangement.

4. Noninvasive Vagal Nerve Stimulation (gammaCore)

The gammaCore device stimulates the vagus nerve, a major nerve connecting the brain to multiple body systems.

Users place the device against the neck for brief stimulation sessions lasting about two minutes.

This stimulation sends signals to the brain that may modulate pain pathways and reduce migraine activity.

In addition to migraine, gammaCore has also been cleared for certain other headache disorders, including cluster headache.

However, the device is often costly and requires ongoing access through prescriptions and subscription-style payment models.

5. Remote Electrical Neuromodulation (Nerivio)

Nerivio is a wearable device placed on the upper arm.

Unlike other neuromodulation therapies that stimulate nerves in the head or neck, Nerivio uses a mechanism called conditioned pain modulation.

The device creates a controlled stimulation signal in the arm that activates the brain’s natural pain-inhibiting pathways. In response, the brain reduces pain signals elsewhere—including migraine pain in the head.

The device is controlled by a smartphone app and runs for 45 minutes per session.

It can be used:

• Acutely during migraine attacks

• Preventively every other day

Nerivio is also notable for its pediatric approval, allowing use in children as young as eight years old.

6. Relivion

Relivion is a head-mounted device that stimulates both trigeminal nerves in the forehead and occipital nerves in the back of the head.

These two nerve systems converge in the lower brainstem, which plays a key role in migraine pain processing.

By stimulating both pathways simultaneously, Relivion aims to provide broader neuromodulation of migraine circuits.

The device is typically used for sessions lasting 45–60 minutes and is designed to be more comfortable than earlier trigeminal nerve stimulation devices.

Cost and Access Remain Major Barriers

Despite their potential benefits, neuromodulation devices face one major challenge: access.

Most neuromodulation therapies are not widely covered by insurance, making them difficult for many patients to afford.

Some exceptions exist. For example:

• Veterans receiving care through the U.S. Veterans Administration often have access to these devices.

• Certain pharmacy benefit programs have begun covering specific devices in limited populations.

However, for most patients, out-of-pocket costs remain a significant barrier to adoption.

Who May Benefit Most from Neuromodulation

Neuromodulation can be considered for many types of migraine patients.

According to headache specialists and guidance from the American Headache Society, ideal candidates may include:

• People who do not respond well to medications

• Individuals who cannot tolerate medication side effects

• Patients at risk of medication overuse headache

• Those who prefer non-drug therapies

• Children and adolescents

• Patients planning pregnancy or currently pregnant

• Individuals with multiple medications and risk of drug interactions

Neuromodulation can also be used in combination with medications, serving as an additional tool in comprehensive migraine management.

What Results Can Patients Expect?

Clinical trials suggest that several neuromodulation devices can achieve results comparable to certain acute migraine medications.

Many studies show improvements in:

• Pain relief

• Pain freedom

• Reduction in monthly migraine days

Preventive effects may be slightly less pronounced than those seen with some newer CGRP-targeting medications, but the absence of medication side effects makes neuromodulation appealing for many patients.

Experts typically recommend trying a neuromodulation device for two to three months to determine whether it provides meaningful benefit.

Trying Different Devices

If one neuromodulation device does not work, it does not mean others will fail as well.

Different devices stimulate different nerves and pathways. Because of these varying mechanisms, patients who do not respond to one device may respond well to another.

This approach mirrors migraine medication management, where trying therapies with different mechanisms often leads to better results.

Implantable Neuromodulation Devices: Not Ready Yet

While research continues on implantable neuromodulation devices for migraine, current evidence does not support their routine use.

Several large studies evaluating implanted occipital nerve stimulators failed to meet primary effectiveness goals. In addition, implantable devices carry surgical risks such as infection, device migration, and procedural complications.

For now, most headache specialists recommend focusing on noninvasive neuromodulation, which offers safer and more accessible treatment options.

The Future of Neuromodulation

Neuromodulation represents one of the fastest-growing areas of migraine research.

Future progress may include:

• Improved device designs

• Lower costs and better insurance coverage

• Expanded clinical research

• More personalized stimulation protocols

According to experts, the biggest challenge moving forward may not be technology—it may be ensuring patients have access to these therapies.

As migraine treatment continues to evolve, neuromodulation offers a promising path forward for people seeking safe, flexible, and drug-free migraine management options.